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ABSTRACT 
Objective: The aim of this study was to develop polymer coated sustained release tablet using sorafenib and silibinin combination for the treatment 
of hepatocellular carcinoma. 
Methods: The qualitative analysis such as weight variation, friability, hardness, interaction studies, disintegration and in vitro release were 
performed to validate formulated tablets. We have maintained the acceptable official limits for weight variation, friability, hardness and 
disintegration time according to prescribed pharmacopoeial recommendation. In vitro drug release studies were performed using USP-II (paddle 
type) dissolution apparatus. The MTT assay was performed for assessment of Cell viability of drug combination for tablet formulation. Molecular 
docking studies have been performed to determine the combinatorial mode of action for the tablet formulation. 
Results: Friability and weight variation were less than 1% for each formulation, which were within range of prescribed pharmacopoeial 
recommendation. The hardness of 20 tablets showed 5-6.5Kg/cm2 for all formulations 5-6.5Kg/cm2
Conclusion: The present study reports for the first time a novel formulation for sustained release and reduced toxicity of sorafenib with enhanced 
inhibitory effect of the drug combination on cancerous hepatic cell line as well collaborative mechanism of action for the formulation. 
. The optimized formulation resulted in 98% 
drug release after 28 h. The present study reports the synergistic effects of drug combination to inhibit cell growth in HepG2 cell line. Molecular 
docking studies showed that sorafenib has high binding affinity for B-Raf vascular endothelial growth factor receptor β and protein kinase B. 
Silibinin showed binding affinity with MAP kinase-11, protein phosphatase 2 A and tankyrase. 
Keywords: Sustained release, Pullulan, Combinational treatment, Silibinin, Silymarin, Sorafenib, Hepatocellular Carcinoma 




Hepatocellular carcinoma (HCC) is a life threatening neoplasm 
originated from hepatocytes, representing approximately 80% of 
liver cancer and 3rd
The present study reports for the first time pullulan coated matrix 
tablet having a combination of sorafenib and silymarin/silibinin to 
target hepatocytes. The tablets were made pH specific for sustained 
release into intestinal fluid. The cell viability assay of above 
combination was performed on Hep G2 cell line to elucidate the 
effective dose of this formulation to inhibit growth of cancerous 
hepatic cells. Furthermore, molecular docking of the combination 
revealedthe collective signalling pathway for both synthetic 
(sorafenib) and phytoconstituents (silibinin). The formulation is also 
reducing the toxicity of the synthetic drugs. 
 most common cancer related death [1]. HCC is a 
extremely vascularized and malignant tumor that is responsible for 
poor survival and rapid recurrence in patients [2, 3]. Sorafenib, an 
angiogenesis inhibitor is predominantly used as oral drug for HCC 
treatment [4]. However, long term exposure of sorafenib to the 
hepatic cells can lead to drug resistance as well as the risk of 
rebound growth of tumorigenic cells [5]. Combination of natural 
phytochemicals (silymarin and silibinin) with synthetic (sorafenib) 
treatment is an alternative way for HCC management, due to their 
efficacy to protect normal hepatic cell from tumorigenic hepatocytes 
[6, 7]. The major issue with this type of infirm soluble drugs is to 
confront bioavailability and cellular absorption; however, several 
polymers are prevalent these days to increase bioavailability in the 
GI tract [8-10]. Polymers such as chitosan, pullulan and cyclodextrin 
are well established coating material to maintain sustained release 
of drugs for prolonged therapeutic effect as well as steady drug 
concentration in blood [11-13]. Pullulan is thermally stable, 
biodegradable and water soluble compound which consists of stable 
neutral linear polysaccharide chain of α-1; α-1,6-maltotriose 
monomer [14]. Pullulan has higher affinity to asialo-glycoprotein 
receptors of hepatic sinusoidal cells and is abundantly expressed in 
liver. This unique feature of pullulan has been utilized by 
researchers for targeted drug delivery to the hepatic cells [15, 16]. 
Pullulan based prodrugs can enhance the bioavailability of 
anticancer drugs and improve tumour targeting [17]. 
METHODS AND MATERIALS 
Chemical required 
Hydroxy propyl methyl cellulose, carboxymethyl cellulose, talc 
powder, lactose, distilled water, ethanol, isopropyl alcohol, 
magnesium stearate, croscarmellose sodium Microcrystalline 
cellulose are procured from Himedia (India). Sorafenib was a gift 
from Cipla. Dulbecco’s Modified essential medium (DMEM) 3-(4, 5-
dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), and 
fetal bovine serum (FBS) were purchased from Himedia (India). 
Trypsin-EDTA (1, 10-phenanthrolinemonohydrate o-phenanthroline 
ethylene diaminetetraacetic acid), dimethylsulfoxide (DMSO), 
antibiotic (penicillin-streptomycin solution), silymarin and silibinin 
are procured from Sigma Aldrich (USA). 
Cell culturing  
HepG2 (Human hepatocellular carcinoma) cells were obtained from 
National Centre for Cell Science (NCCS Pune, Maharashtra, India). The 
cell culture medium was DMEM supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 
g/ml streptomycin (Invitrogen, Carlsbad, CA). Cells were grown in cell 
culture media and incubated at 37◦C in a 5% CO2/95% air humidified 
incubator. For experimental purposes, a fully confluent 75 cm2 culture 
flask containing the cells was trypsinized (500 μl of 0.25% trypsin).  
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We have performed cell viability assay to investigate the inhibitory 
effect of sorafenibsilymarin and silibinin individually as well as in 
combination. The MTT-assay was performed on HepG2 cells using 
different concentration of drugs and its combinations for 
determining cell viability [18]. For this, 10 x 103
Further, DMSO (200 µl) was added to each well for solubilization of 
fromazon crystals and plate was read at 550 and 660 nm on a 
microplate reader (Synergy HT, BIO-TEK International, Winooski, 
VT). The percentage viability was calculated by comparing the 
absorbance of control and treated cells. 
 cells were seeded in 
96 well cell culture plates. The cells were incubated with different 
concentration of silymarin, silibinin and sorafenib alone and its 
different combination for 24 and 48 h. Each combination contained 
two types of compounds, one was synthetic (sorafenib) and another 
was plant based compound either silymarin or silibinin according to 
the table 1. After required incubation MTT solution (5 mg/ml) was 
added to the each well and further incubates for 2-3 h.  
  
Table 1: Individual dose and its combination for cell viability assay 
Name of drug Concentration 
Sorafenib 2.5, 5, 10 and 20 µM 
Silymarin 2.5, 5, 10 and 20 µM 
Silibinin 4, 10, 20, 40 and 80 µM 
Combination1 (Sorafenib: silymarin) 5: 5 µM 
Combination2 (Sorafenib: silymarin) 10: 10 µM 
Combination3 (Sorafenib: silibinin) 10: 20 µM 
Combination4 (Sorafenib: silibinin) 20: 40 µM 
 
Drug interaction studies through FTIR 
The drug-drug interaction has been performed using ATR-FTIR 
(Attenuated total reflection-Fourier transform infrared 
spectroscopy, Cary 660 FTIR spectrometer-Agilent Technologies) 
procedure. Sorafenib, silibinin and silymarin individually and in 
combination (sorafenib-silymarinand sorafenib-silibinin in 1:1 ratio) 
diluted with chemically latent compound KBr for pellet preparation. 
These pellets were scanned from 4000 to 400 cm−1 on FTIR for 
spectra analysis. 
Methodology for matrix tablet formulation 
Tablets were formulated using wet granulation method with drugs 
and excipients. Different concentration of each drug (table 2), lactose 
1.2 gram, microcrystalline cellulose 0.8 gram, croscarmellose sodium 
400 mg, and magnesium stearate 100 mg were used to prepare 100 
tablets. All material except HPMC and talc powder were added in a 
tray and mixed using double comb blender for 15-20 min. Dough was 
prepared using minimal amount of 5% HPMC solution (1-2 ml only). 
Subsequently, granules were produced using 12 mesh sieve and air 
dried at 45-50 ° for 2 h. These granules were mixed with 100 mg talc 
powder using double comb blender. Tablets were punched according 
to their theoretical weight using punching machine. 
Pullulan coating 
Coating was done using 2% pullulan (0.05% glycerol-mili-Q water) 
solution. Spray coating were done for 3 min and liquid component of 
coating material were air dried through passing of air on the 
tumbling pan for complete dehydration. The multiple cycle of 
spraying were done for complete coating of the tablets. 
 
Table 2: Concentration of each drug in different formulation 
Name of formulation Drug concentration per tablet Theatrical Weight of each tablet 
Formulation 1 Sorafenib: Silymarin (1: 1) (7 mg+7 mg) 40.0 mg 
Formulation 2 Sorafenib: Silibinin (1: 1) (4.5 mg+4.5 mg) 36.0 mg 
Formulation 3 Sorafenib: Silibinin (0.7: 1) (3.5 mg+4.5 mg) 34.5 mg 
 
Qualitative evaluation of tablets 
Monsanto hardness tester was used to measure hardness (n=10) of 
the tablet and unit was Newton/meter. The friability was measured 
utilizing Roche friabilator and total five tablets were taken from each 
formulation. First, pre-weighed tablets kept in friabilator for 
rotation at 25 rpm speed for 4 min and then reweighed 
afterremoval. Weight loss percentage was calculated. The 
disintegration test apparatus was used for disintegration time 
calculation by keeping one tablet placed in each basket. This 
procedure has been performed with both acidic medium (0.1N HCl) 
and basic medium (phosphate buffer pH 7.4). Disintegration time 
calculated using stopwatch. Weight variation was carried out to 
ensure proper amount of drug in each tablet. The test was 
accomplished after weighing 20 tablets individually using analytical 
balance and then calculating the average weight.  
Dissolution test 
In vitro drug release studies were performed using USP-II (paddle 
type) dissolution apparatus, on the rotational pace of 50 rpm at 
37±0.5 °. Dissolution of formulating tablets was performed under 
both acidic and basic conditions. 900 ml of 0.1 M HCl was used for 
initial 2 h followed by phosphate buffers (pH 7.4) for 28 h. Sample 
(10 ml) was withdrawn at specific interims and the same volume of 
pre-warmed (37±0.5 °) fresh dissolution medium was supplanted to 
keep up the volume steady. The sample was filtered with Whatman 
filter paper and different wavelength (272 nm, 288 nm and 287 nm 
for Sorafenib, silymarin and silibinin respectively) were used to 
calculate the cumulative drug content in each formulation using 
suitable dilution. The dissolution test was  
Molecular docking and metabolic pathway analysis 
An extensive review was performed to identify the effective target 
proteins for binding of sorafenib and silibinin. Identified proteins were 
studied for their role in hepatocarcinogenesis. All proteins were 
directly imported from Protein Data Bank (PDB) into the Protein 
Preparation Wizard of Maestro9.6 and analyzed for their unordered 
side chains, loops and missing atoms. Moreover, water atoms were 
removed and the missing side chains were validated by Prime3.5 
program. Protein optimization and minimization was performed 
for hydrogen atom addition and atomic charge assignment, 
respectively. Ligands were sketched on 2D-sketcher for structure 
designing. Later, low energy conformations were achieved for both 
ligands through ligand preparation (LigPrep2.8 module) in 
Maestro workspace. Extra Precision (XP) program of Glide6.1 was 
utilized to dock both ligands with each receptor. The flexible 
ligand-receptor docking was performed for the conformation 
generation and only low energy conformations were retained. The 
Predicted signalling pathway was prepared utilizing glide score of 
ligand receptor docking.  
Statistical analysis 
The results were studied using either one way or two ways 
ANOVA (analysis of variance) and p-value<0.05 was measured 
to be statistically significant using Graph Pad Prism software, 
U. S. A. 
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Effect of individual dose of sorafenib, silymarin and silibinin on 
HepG2 cell line 
Dose and time dependent effects of sorafenib, silymarin and silibinin 
were determined at different concentrations (2.5, 5, 10, 20 and 40 
μM) in HepG2 cells by performing MTT assay. As shown in fig. 1. All 
the three compounds did not exhibit any significant effect at 24 h. 
However at 48 h, cell viability was significantly reduced to 87%, 
88%, 74% and 67% (P<0.001) at 5-40 μM concentration of 
sorafenib. Further, plant based compound, Silymarin also showed 
significant effect at 48 hr showing reduced cell viability from 78% to 
67% (P<0.001) at concentrations of 5–40 μM. Similar trend was 
exhibited by another plant based compound, Silibinin that reduced 
the cell viability by 84%, 75%, 66%, 71%, and 65% (P<0.001) at 48 
h incubation with 2.5-40 μM concentration. 
 
 
Fig. 1: Percent viability of Hep G2 cell line after individual drugs exposure, (n=5; mean+SD; *<0.05; **<0.01; and ***<0.001 as compared to 
control cells) 
 
Formulation of tablets and evaluation of their efficacy 
Drug-drug interaction studies  
IR spectra of each drug and combination (sorafenib with 
silymarin/silibinin) component were carried out for drug-drug 
interaction analysis (fig. 2 A and 2 B). No major differences in the 
FTIR. patterns of pure drug and combination were observed.  
The FTIR studies confirmed that there is no interaction between 
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Fig. 2A: FTIR spectra of individual drugs (Sorafenib, Silymarin and Silibinin) 
 
 
Fig. 2B: FTIR spectra of combination (Sorafenib: Silymarin and Sorafenib: Silibinin) 
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We formulated three types of pullulan coated tablets, sorafenib in 
combination with silymarin and/or silibinin in 1:1 ratio and 
sorafenib with silibinin in 0.7:1 ratio. Small variation in the 
qualitative study of each formulation (F1, F2 and F3) was indicative 
of uniform compression procedure throughout tablet formulation. 
All formulations were prepared utilizing 1-3% of pullulan coating; 
however, the best result of coating was found with 2% of pullulan in 
0.05% glycerol solution (Significant batch of each formulation has 
been illustrated). Different qualitative parameters including 
hardness, friability and weight variety of formulated matrix 
tablets were analysed to identify the best combination of pullulan 
coated synthetic and herbal drugs. Friability and weight variation 
were less than 1% for each formulation, which were within range of 
prescribed pharmacopoeial recommendation. The hardness of 20 
tablets showed 5-6.5Kg/cm2 for all formulations which was within 
the acceptable official limits (table 3, fig. 3). 
 








Weight variation % 
(n=10; mean+SD) 
Disintegration 
time in 0.1N HCl 
Disintegration 
time in phosphate 
buffer 
formulation 1 (F1) 0.53±0.001 5±0.09 44.16±0.29 No Disintegration 30 min 
formulation 2 (F2) 0.41±0.012 6.5±0.08 36.58±0.41 No Disintegration 20 min 
formulation 3 (F3) 0.43±0.001 6.2±0.019 37.66±0.27 No Disintegration 15 min 
 
 
Fig. 3: Combination tablets A) formulation 1; B) Formulation 2; 
C) Formulation 3 
 
Disintegration analysis 
The enteric coating capability of pullulan made the tablets unable to 
disintegrate in 0.1N HCl. Five tablets were kept in 0.1N HCl for 2 h, 
but no disintegration reported throughout duration. However, when 
the medium was changed with phosphate buffer it took (pH 7.4) 30, 
20 and 15 min to disintegrate formulation 1, formulation 2 and 
formulation 3 respectively (table 3). 
Dissolution studies 
Enteric coating pullulan did not show any release in 0.1N HCl within 
2 h in each formulation. The dissolution medium was changed with 
phosphate buffer and the drug release was observed. In formulation 
1 sorafenib released up to 67% whereas in same formulation 
silymarin has released up to 90 %. Formulation 2 showed release of 
98% for both sorafenib and silibinin. On the other hand, formulation 
3 showed moderate release of both drugs that was 73% and 84% for 
sorafenib and silibinin, respectively. The P value was less than 0.001 
for each formulation showed its significance. Due to controlled 
release medium each formulation has taken minimum 28 hr to 
release its maximum amount (fig. 4) 
  
 
Fig. 4: Percent drug release of individual drugs in each formulation (n=5; mean+SD) 
 
Effect of combinational treatment on HepG2 Cell lines 
For evaluation of the combinational effect of synthetic and herbal drug, 
different drug formulations were prepared. HepG2 cells were treated 
with combination 1 (Sorafenib: silymarin 5: 5 µM) showed reduced 
cell viability by 77% and 62% (P<0.01) at 24 and 48 h of incubation. 
Whereas combination 2 (Sorafenib: silymarin 10: 10 µM) showed to be 
more effective than the combination 1 and the cell viability reduced to 
61% and 54% (P<0.001) at same time points. Combination 3 
(Sorafenib: silibinin 10: 20 µM) and Combination 4 (Sorafenib: 
silibinin 20: 40 µM) reduced cell viability by 61% and 51% (P<0.001) 
at 24 h, whereas at 48 h it found to be more effective and reduced cell 
viability by 52% and 45% (P<0.001), respectively. From the above 
results it is clear that combination 4 showed better cytotoxic effects 
against hepatocellular carcinoma cells in comparison to the individual 
compounds or other combinations (fig. 5). 
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Fig. 5: Percent viability of Hep G2 cell line after combination of drugs exposure, (n=5; mean+SD; **P<0.01and ***P<0.001 as compared to 
control cells) 
 
Molecular docking analysis 
We have retrieved the target proteins involved in hepato-
carcinogenesis through extensive literature survey. Molecular 
docking helped us to understand and analyze the binding efficacy 
between ligands and receptors. Different poses of ligands were 
allowed to dock with each receptor and were reviewed according to 
their Glide Score. Sorafenib has high binding affinity for B-Raf (-
12.804), vascular endothelial growth factor receptor β (VEGFR-β) (-
12.651) and protein kinase B (AKT) (-8.488) which provided an 
antagonist for inhibition of angiogenesis and cell proliferation [Table 
4; fig. 6; Supplementary file]. Silibinin showed binding affinity with 
number of receptors such as MAP kinase-11 (p38) (-11.471), protein 
phosphatase 2 A (PP2A) (-6.781), tankyrase (-11.221) and predicted 
as inhibitor of cell proliferation, survival and differentiation [Table 
4; fig. 6; Supplementary file]. However, both ligands have shown 
good binding affinity with epidermal growth factor receptor 1 
(EGFR-1), fibroblast growth factor receptor (FRFR-1) and 
hepatocyte growth factor receptor (c-Met) that showed inhibited cell 
proliferation and survival through antagonist binding. Therefore, 
overall docking score of sorafenib/silibinin with respective protein 
hypothesized a collaborative signalling pathway through inhibition 
of Ras/Raf/MEK/ERK, PI3K/AKT/mTOR, Wnt/β-catenin routes for 
treatment of HCC [fig. 7]. 
  
 
Fig. 6: Docking poses of (A and A’) Sorafenib with VEGFR-β (vascular endothelial growth factor receptor β) and (B and B’) Silibinin with 
p38 (Mitogen-activated protein kinase 11) 
 
Table 4: Docking score of both ligands with different receptors 
Name of receptor (PDB ID)  Glide score with sorafenib Glide score with silibinin 
VEGFR2 (4ASD) -12.651 -8.395 
B-Raf (5HI2) -12.804 -9.466 
AKT (3CQU) -8.488 -6.911 
FGFR1 (5B7V) -9.034 -8.659 
EGFR(5HCX) -8.144 -8.837 
HGFR (5HLW) -7.705 -9.116 
MAPK11 (3HEC) -9.625 11.471 
Tankyrase (5FPF) -10.870 -11.221 
PP2A (3K7V) -4.336 -6.781 
 
The glide score<-7.00 represents permissible affinity of particular 
drag to their receptor and can act as antagonist to respective protein 
(vascular endothelial growth factor receptor (VEGFR-β); proto-
oncogene B-Raf (B-Raf); protein kinase B-1(AKT-1); Fibroblast 
growth factor receptor 1(FGFR1); epidermal growth factor receptor 
(EGFR); hepatocyte growth factor receptor (HGFR); Mitogen-
activated protein kinase 11 (p38); tankyrase; protein phosphatase 2 
A (PP2A)) 
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Fig. 7: The target proteins which are involved in hepatocarcinogenesis can be inhibited by sorafenib (SF) and silibinin (SL). Sorafenib has 
antagonist effect of vascular endothelial growth factor receptor (VEGFR-β), proto-oncogene B-Raf and protein kinase B-1(AKT-1). 
However, silibinin is involved in inhibition of mitogen-activated protein kinases (p38), AKT, Protein kinase B, tankyrase and protein 
phosphatase 2 A (PP2A). MEK kinases (MEK); extracellular signal-regulated kinase (ERK); phosphatidylinositol-3-kinase (PI3K); Insulin-
like growth factor receptor (IGFR); Pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1); Mammalian target of rapamycin 
(mTOR); Tumor protein p53 (Tp53); p53 unregulated modulator of apoptosis protein (PUMA); BCL-2-associated death promoter (BAD); a 
family of G-protein-coupled receptor proteins for WNT/β-catenin signalling pathway (Frizzled); Low-density lipoprotein receptor-related 
proteins 5 and 6 (LRP5/6); Downstream effector Dishevelled (DSH); Glycogen synthase kinase 3β (GSK-3β,); a G-protein signalling 
molecule (AXIN); Casein kinase (CK); Adenomatous polyposis coli (APC) 
 
DISCUSSION 
The study successfully develops sustained release pullulan-coated 
tablets containing sorafenib in combination with silymarin and 
silibinin. Silymarin and its major constituent silibinin have 
hepatoprotective and cytotoxic nature against cancerous hepatic 
cells [19, 20]. Our previous report on combinational formulation also 
suggested that plant based compound with synthetic drugs are more 
effective and less toxic for HCC treatment [21]. Interestingly, 
Silibinin and sorafenib follow same pathways to inhibit cell growth 
[22]. Taking this phenomenon into consideration, we have used 
silymarin and its major constituent silibinin in combination with 
sorafenib for tablet formulation. Pullulan coated enteric tablets were 
prepared for sustained release of drugs in intestinal tract. The 
enhanced solubility of drug is expected in intestinal fluids with shift 
of dissolution medium from acidic to basic phase [9, 23]. Our results 
are in accordance with the earlier reports and as we have observed 
that after changing the pH of dissolution medium from 0.1N HCl to 
phosphate buffer (pH 7.4) enhanced release of drug/s were 
obtained. This is the first report of a novel formulation using 
synthetic and herbal drug in sustained release for the treatment of 
HCC. The physical parameters of each formulation such as average 
weight, hardness, friability and disintegration capacity of tablets 
were within the permissible range and assured the formulation 
quality. Moreover, dissolution of each drug started in a controlled 
manner and maximum release occurred within 28 h, which 
represented the sustained release of both drugs at specific pH as a 
result of pullulan coating. Similarly, the pH specific controlled 
release of drugs through pullulan or other biopolymers have been 
earlier reported by researchers to maintain plasma concentration 
for longer duration [11, 24]. Our dissolution studies demonstrated 
that formulation 2, (sorafenib with silibinin in 1:1 ratio) showed 
maximum release up to 98% for both drugs after 28 h. However, it 
was quite lower in formulation 3 (73% and 84 for sorafenib and 
silibinin, respectively). The lowest release of sorafenib was observed 
in presence of silymarin in formulation 1 (67% and 90% for 
sorafenib and silymarin, respectively). This observation gave an idea 
that instead of silymarin complex, silibinin can be used as a better 
option for combination treatment. However, not much work has 
been done on the combination of sorafenib and silibinin as for today. 
A study conducted by Gu and coworkers reported that silibinin in 
combination with sorafenib/gefitinib inhibits growth of cancerous 
cell lines, but their work mainly emphasize on the efficacy of 
silibinin-gefitinib combination. [25]. Our result strengthens the idea 
that sorafenib in combination with silibinin have synergestic effect 
on HCC cell line. The maximum growth inhibition effect of each drug 
was seen at its higher concentration (40 µM and 80 µM for 
sorafenib/silymarin and silibinin, respectively). However, in 
combination, 20 µM of silibinin with 10 µM sorafenib was enough to 
reduce cell viability up to 59% after 24 hour incubation. The overall 
cell viability assay affirmed that sorafenib and silymarin has 
cytotoxicity against tumorigenic hepatic cells, whereas combination 
of sorafenib and silibinin showed synergistic growth inhibition of 
cancer-bearing hepatocytes with maximum sustained release.  
The molecular docking studies were performed to elucidate 
signalling pathways affected by combinatorial formulations. The 
docking studies can be considered as an emerging tool in discovery 
of new targets [26, 27]. We have observed that sorafenib and 
silibinin inhibit their specific pathways along with other signalling 
routes which are involved in hepatocarcinogenesis. The result 
showed that sorafenib was inhibiting angiogenesis and cell 
proliferation through binding with VEGFR-β, B-Raf and Protein 
kinase B. Whereas, silibinin acted as antagonist for wnt/β-catenin 
pathway through inhibition of AXIN1 activation (binding with 
tankyrase) and β-catenin dephosphorylation (binding with PP2A) 
[28, 29]. Moreover, silibinin can also inhibit cell survival through 
antagonist binding of c-Met and MAP Kinase-11(p38). Sorafenib and 
silibinin have antagonist binding with EGFR1 and FGFR1 for 
inhibition of cell proliferation and angiogenesis, respectively. The 
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studies by other researchers have also shown similar inhibitory 
effects on various cancerous cell-lines after incubation with both 
drugs individually [22, 30, 31]. The overall pathway deciphers the 
collaborative signalling for inhibition of tumorigenesis through 
down regulation of cell proliferation, angiogenesis and cell survival. 
CONCLUSION 
Polymer coated tablet formulations are efficient and established 
methods to accomplish sustained release of drugs. Pullulan, a 
thermally stable and neutral linear polysaccharide, is an amazing 
polymer for sustain release and liver targeting. The present study 
concludes that pullulan coated tablet has the ability to maintain 
steady drug concentration in blood. Sorafenib and silibinin 
combination can assure the sustained release of both drugs and an 
effective combination for the treatment of hepatocellular carcinoma 
through inhibition of cell survival, proliferation and differentiation. 
However, preclinical studies are required for further analysis. 
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